Triomics, a startup focused on leveraging artificial intelligence to streamline cancer care, has successfully secured $22 million in a Series B funding round. The investment was spearheaded by Battery Ventures, with participation from existing backers including Nexus Venture Partners, Lightspeed, and Y Combinator. The company plans to utilize these funds to scale its operations and enhance its platform, which is specifically engineered to reduce the heavy administrative workload currently faced by oncology centers.

As medical breakthroughs continue to improve patient outcomes, the volume and complexity of oncology records have surged. Today’s patient charts frequently encompass thousands of pages, ranging from detailed physician notes and pathology reports to complex imaging scans. Triomics tackles this data overload by deploying large language models tailored for oncology, enabling the automation of labor-intensive processes such as clinical trial matching and patient appointment preparation. By embedding directly into existing clinical workflows, the platform provides physicians with verifiable patient summaries, eliminating the need to navigate multiple disparate software systems.

In addition to its clinical utility, the platform aids healthcare facilities in maintaining regulatory compliance by automating the submission of tumor reports to government registries. The technology has already gained traction at top-tier medical institutions, including Memorial Sloan Kettering and Yale Cancer Center. Despite a crowded market of AI medical scribe providers, Triomics has demonstrated significant growth, reporting a fourfold expansion in its enterprise customer base and a tenfold increase in annualized recurring revenue over the last twelve months.

Key Takeaways

• Triomics raised $22 million in Series B funding led by Battery Ventures to scale its AI-driven oncology platform.
• The platform uses specialized large language models to automate clinical trial matching, appointment prep, and regulatory reporting.
• The company has seen rapid growth, achieving a tenfold increase in annualized recurring revenue and a fourfold increase in enterprise clients over the past year.

Editor’s Analysis & Impact

The success of Triomics highlights a critical shift in healthcare technology: the transition from general-purpose AI tools to highly specialized, domain-specific solutions. By focusing exclusively on the complex, data-heavy field of oncology, Triomics is solving a high-value problem that generic medical scribes often fail to address. The company’s ability to integrate directly into existing clinical workflows is a key competitive advantage, as it minimizes the ‘friction’ that often prevents hospital adoption of new software. Looking ahead, as healthcare systems face increasing pressure to reduce administrative costs and improve patient throughput, platforms that can automate regulatory compliance and clinical data synthesis will likely become essential infrastructure. The rapid revenue growth suggests that the market is ready to move beyond pilot programs and invest in scalable, AI-integrated clinical operations.

Frequently Asked Questions

Q: What is the primary function of the Triomics platform?
A: Triomics uses AI to automate administrative tasks in oncology, such as clinical trial matching, appointment preparation, and the submission of tumor reports to regulatory registries.

Q: Which major institutions are currently using Triomics technology?
A: The platform has been adopted by prominent medical institutions, including Memorial Sloan Kettering and Yale Cancer Center.